318 related articles for article (PubMed ID: 30479461)
1. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
Cabrero-de Las Heras S; Martínez-Balibrea E
World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
[TBL] [Abstract][Full Text] [Related]
2. The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets.
Wang J; Ouyang X; Zhu W; Yi Q; Zhong J
Cancer Control; 2024; 31():10732748241241162. PubMed ID: 38533911
[TBL] [Abstract][Full Text] [Related]
3. The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology.
La Cognata V; Morello G; Guarnaccia M; Cavallaro S
Prog Neurobiol; 2024 Apr; 235():102587. PubMed ID: 38367748
[TBL] [Abstract][Full Text] [Related]
4. Chemokines and Their Receptors: Predictors of Therapeutic Potential in Tumor Microenvironment on Esophageal Cancer.
Huang CG; Liu Q; Zheng ST; Liu T; Tan YY; Peng TY; Chen J; Lu XM
Dig Dis Sci; 2024 May; 69(5):1562-1570. PubMed ID: 38580886
[TBL] [Abstract][Full Text] [Related]
5. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
Ullah A; Jiao W; Shen B
Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
[TBL] [Abstract][Full Text] [Related]
6. Pro-inflammatory Cytokines and CXC Chemokines as Game-Changer in Age-Associated Prostate Cancer and Ovarian Cancer: Insights from Preclinical and Clinical Studies' Outcomes.
Ullah A; Chen Y; Singla RK; Cao D; Shen B
Pharmacol Res; 2024 May; ():107213. PubMed ID: 38750677
[TBL] [Abstract][Full Text] [Related]
7. Targeting G protein-coupled receptor for pain management.
Li H; Wang R; Lu Y; Xu X; Ni J
Brain Circ; 2017; 3(2):109-113. PubMed ID: 30276310
[TBL] [Abstract][Full Text] [Related]
8. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.
Vacchini A; Mortier A; Proost P; Locati M; Metzemaekers M; Borroni EM
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486423
[TBL] [Abstract][Full Text] [Related]
9. Vaccines for colorectal cancer: an update.
Sarvizadeh M; Ghasemi F; Tavakoli F; Sadat Khatami S; Razi E; Sharifi H; Biouki NM; Taghizadeh M
J Cell Biochem; 2019 Jun; 120(6):8815-8828. PubMed ID: 30536960
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
11. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
Front Oncol; 2019; 9():1555. PubMed ID: 32117786
[No Abstract] [Full Text] [Related]
12. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
[TBL] [Abstract][Full Text] [Related]
14. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
Chen MC; Baskaran R; Lee NH; Hsu HH; Ho TJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
J Cell Physiol; 2019 Jul; 234(7):11822-11834. PubMed ID: 30552676
[TBL] [Abstract][Full Text] [Related]
15. The Significance of CXCL1 and CXCL8 as Well as Their Specific Receptors in Colorectal Cancer.
Łukaszewicz-Zając M; Pączek S; Mroczko P; Kulczyńska-Przybik A
Cancer Manag Res; 2020; 12():8435-8443. PubMed ID: 32982437
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
17. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
18. Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.
Mollica Poeta V; Massara M; Capucetti A; Bonecchi R
Front Immunol; 2019; 10():379. PubMed ID: 30894861
[TBL] [Abstract][Full Text] [Related]
19. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers.
Do HTT; Lee CH; Cho J
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991604
[TBL] [Abstract][Full Text] [Related]
20. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance.
Tuomisto AE; Mäkinen MJ; Väyrynen JP
World J Gastroenterol; 2019 Aug; 25(31):4383-4404. PubMed ID: 31496619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
